Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings

30.04.24 00:30 Uhr

Werte in diesem Artikel
Aktien

40,25 EUR -0,02 EUR -0,05%

17,50 PLN 0,20 PLN 1,16%

Indizes

PKT PKT

18.068,2 PKT 66,2 PKT 0,37%

6.941,3 PKT 25,4 PKT 0,37%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

182,5 PKT 0,3 PKT 0,16%

501,8 PKT 2,8 PKT 0,55%

9.599,4 PKT 22,8 PKT 0,24%

18.155,0 PKT 115,0 PKT 0,64%

18.099,7 PKT 84,5 PKT 0,47%

3.329,0 PKT -27,8 PKT -0,83%

7.099,8 PKT 19,3 PKT 0,27%

3.322,7 PKT -30,5 PKT -0,91%

2.435,1 PKT -22,4 PKT -0,91%

3.700,4 PKT -63,0 PKT -1,67%

For the quarter ended March 2024, Qiagen (QGEN) reported revenue of $458.8 million, down 5.5% over the same period last year. EPS came in at $0.46, compared to $0.53 in the year-ago quarter.The reported revenue represents a surprise of +0.73% over the Zacks Consensus Estimate of $455.5 million. With the consensus EPS estimate being $0.44, the EPS surprise was +4.55%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $25 million versus $23.82 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.1% change. Sales by Product Groups- Diagnostic solutions- QuantiFERON: $101 million versus $105.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.8% change. Sales by Product Groups- Genomics / NGS: $55 million versus $50.95 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a 0% change. Sales by Product Groups- Other: $11 million versus $11.67 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -35.3% change. Sales by Product Groups- PCR / Nucleic acid amplification: $68 million versus $70.87 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -11.7% change. Sales by Product Groups- Diagnostic solutions- NeuMoDx: $9 million versus $11.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -30.8% change. Sales by Product Groups- Sample technologies: $155 million versus $146.53 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -10.4% change. Sales by Product Groups- Diagnostic solutions: $170 million versus the three-analyst average estimate of $174.25 million. The reported number represents a year-over-year change of +4.3%. Revenue- Life Sciences: $215 million versus $208.53 million estimated by two analysts on average. Sales by Product Groups- Diagnostic solutions- Other: $35 million versus the two-analyst average estimate of $35.07 million. Revenue- Molecular Diagnostics: $244 million compared to the $247.55 million average estimate based on two analysts. The reported number represents a change of -2.4% year over year. View all Key Company Metrics for Qiagen here>>>Shares of Qiagen have returned -3.1% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf QIAGEN

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf QIAGEN

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu QIAGEN N.V.

Analysen zu QIAGEN N.V.

DatumRatingAnalyst
21.05.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02.05.2024QIAGEN NeutralUBS AG
02.05.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyDeutsche Bank AG
DatumRatingAnalyst
21.05.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyDeutsche Bank AG
16.04.2024QIAGEN BuyDeutsche Bank AG
16.02.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
02.05.2024QIAGEN NeutralUBS AG
02.05.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN HoldJefferies & Company Inc.
01.03.2024QIAGEN NeutralUBS AG
DatumRatingAnalyst
17.02.2021QIAGEN VerkaufenIndependent Research GmbH
14.12.2020QIAGEN VerkaufenDZ BANK
10.12.2020QIAGEN VerkaufenIndependent Research GmbH
24.11.2020QIAGEN VerkaufenIndependent Research GmbH
11.11.2020QIAGEN VerkaufenDZ BANK

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für QIAGEN N.V. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"